AbbVie and RemeGen Announce Exclusive Licensing Agreement to Develop A Novel Bispecific Antibody for Advanced Solid Tumors

AbbVie (NYSE: ABBV) and RemeGen today announced an exclusive licensing agreement for the development, manufacturing and commercialization of RC148, a novel investigational Programmed Cell Death-1 ...
The Pharma Letter

AbbVie punts up to ~$5 billion on RemeGen bispecific antibody

US pharma major AbbVie and China’s RemeGen today announced an exclusive licensing agreement for the development, ...
The Scientist

Programmed Cell Death

This finding, he suggests, helps link the study of cell death in the worm and oncogenesis in people. "There were a number of papers that had suggested a relationship between cell death and oncogenesis ...
Medical Dialogues

Correlation between cancer cachexia and immune-related adverse events in HCC: Study

Immune checkpoint inhibitors (ICIs), including antibodies against the programmed cell death protein 1/ligand 1 (PD-1/L1) ...
Frontiers

Biomarker-Guided Strategies in NSCLC Immunotherapy

The field of immunotherapy has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC), particularly ...
Pharmabiz

AbbVie & RemeGen enter exclusive licensing agreement to develop novel bispecific antibody for advanced solid tumours

AbbVie & RemeGen enter exclusive licensing agreement to develop novel bispecific antibody for advanced solid tumours: North Chicago, Illinois Tuesday, January 13, 2026, 14:00 Hrs ...